SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001720725-22-000036
Filing Date
2022-04-22
Accepted
2022-04-22 16:56:08
Documents
5
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 DEF 14A proxy22.htm DEF 14A 433226
2 image.jpg GRAPHIC 10267
3 image1.jpg GRAPHIC 2303
4 proxycard2022.jpg GRAPHIC 75784
5 proxycard22022.jpg GRAPHIC 70876
  Complete submission text file 0001720725-22-000036.txt   654018
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39112 | Film No.: 22846316
SIC: 2836 Biological Products, (No Diagnostic Substances)